On March 2, 2023 Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format (Press release, Aptose Biosciences, MAR 2, 2023, View Source [SID1234628033]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer 33rd Annual Healthcare Conference
Presentation Details:

Date: Monday, March 13, 2023
Time: 12:40 – 1:10 PM ET
Format: Fireside Chat – William G. Rice, PhD, Chairman, President and Chief Executive Officer, Aptose, with Matthew Biegler, Senior Analyst, Emerging Biotechnology, Oppenheimer
Webcast: LINK
The audio webcast will be archived shortly after the live event and will be available through the Aptose website, www.aptose.com.

The Aptose management team will be hosting virtual one-on-one meetings during the conference. To schedule a one-on-one meeting, please contact your conference representative.